ArticleNature cancer2020
Alterations in
Abstract read
In one paragraph
Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 158 citations in OpenAlex.
- A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.JCO precision oncology · 2025Trial
- Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Phase II Study of Copanlisib in Patients With Tumors WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance.The Journal of clinical investigation · 2026Review
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer.Drugs · 2026Review
- Review
- Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.The Journal of biological chemistry · 2026Article
- Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Nature · 2026Article
- Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.The breast journal · 2026Article
- Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.BMC cancer · 2025Article
- Revealing the Angiogenic Signature ofCancers · 2025Article
- Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.JCO precision oncology · 2025Observational
- Liquid biopsy in breast cancer: Redefining precision medicine.The journal of liquid biopsy · 2025Review
- AdaSemb: an adaptive knowledge-driven deep learning framework integrating cancer protein assemblies for predicting PI3Kα inhibitor response and resistance.Briefings in bioinformatics · 2025Article
- Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis.NPJ breast cancer · 2025Article
- Emerging Mechanisms of Therapy Resistance in Metastatic ER+ Breast Cancer.Endocrinology · 2025Review
- APOBEC3 mutagenesis drives therapy resistance in breast cancer.Nature genetics · 2025Article
- The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.NPJ breast cancer · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 4 institutions in 1 country.
Pedram RazaviDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. razavip@mskcc.org.ORCID http://orcid.org/0000-0003-4236-0576
Maura N DicklerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Payal D ShahDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Weiyi ToyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David N BrownDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8249-3632
Helen H WonMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bob T LiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6661-8733
Ronglai ShenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Neil VasanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shanu ModiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Komal JhaveriDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Betty Ann CaravellaWeill Cornell Medical College, New York, NY, USA.
Sujata PatilWeill Cornell Medical College, New York, NY, USA.
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stephen ZamoraDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aimee M CowanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabeth ComenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andy SinghGuardant Health, Inc., Redwood City, CA, USA.
Anne CoveyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Clifford A HudisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Larry NortonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rebecca J NagyGuardant Health, Inc., Redwood City, CA, USA.
Justin I OdegaardGuardant Health, Inc., Redwood City, CA, USA.
Richard B LanmanGuardant Health, Inc., Redwood City, CA, USA.ORCID http://orcid.org/0000-0001-8122-4329
David B SolitDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6614-802X
Mark E RobsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mario E LacoutureDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Edi BrogiWeill Cornell Medical College, New York, NY, USA.
Jorge S Reis-FilhoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2969-3173
Mary Ellen MoynahanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maurizio ScaltritiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5522-1447
Sarat ChandarlapatyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandars@mskcc.org.ORCID http://orcid.org/0000-0003-4532-8053
Memorial Sloan Kettering Cancer Center · USGuardant (United States) · USAmerican Society of Clinical Oncology · USUniversity of Pennsylvania · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MTherapeutic approaches to ER mutant breast cancerR01CA204999 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2017 to 2021
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA190642NCI NIH HHS R01 CA204999NCI NIH HHS R01 CA234361
Abstract
Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for
Indexed as
Aromatase InhibitorsBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesEstrogen Receptor ModulatorsFemaleHumansPTEN PhosphohydrolaseReceptors, EstrogenThiazolesAlpelisibAromatase InhibitorsErb-b2 Receptor Tyrosine KinasesEstrogen Receptor ModulatorsPTEN PhosphohydrolasePTEN protein, humanReceptors, EstrogenThiazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.